GlassScriptPhysician profile
Deanna L Winter
NPI 1043268170
$1,995.98
in general payments reported to CMS, 2019-2025
24 companies · $895 in 2025
The $895 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $234 · 2023: $199 · 2024: $668 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,762.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.85 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $236.78 | 2022-2024 | Xarelto |
| Pfizer INC. | $213.16 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $160.35 | 2024-2025 | |
| Biosense Webster, INC. | $145.39 | 2025 | Carto 3 |
| Boston Scientific Corporation | $139.57 | 2025 | Watchman Access System |
| Merck Sharp & Dohme LLC | $128.89 | 2022-2025 | Verquvo |
| Amgen INC. | $104.28 | 2022-2025 | Repatha, Repatha |
| Abbott Laboratories | $89.27 | 2024 | Aveir |
| Astrazeneca Pharmaceuticals LP | $86.38 | 2022-2025 | Farxiga, Wainua |
| Kiniksa Pharmaceuticals International, Plc | $66.75 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $65.94 | 2024-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.93 | 2022-2024 | Lifevest |
| Alnylam Pharmaceuticals INC. | $30.40 | 2025 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $28.26 | 2024 | Opsumit, Uptravi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $26.11 | 2025 | Fibryga |
| Novo Nordisk INC | $23.69 | 2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $20.81 | 2022 | |
| Glaxosmithkline, LLC. | $19.12 | 2025 | Shingrix, Arexvy |
| Daiichi Sankyo INC. | $17.89 | 2025 | Injectafer |
| Scpharmaceuticals INC. | $15.75 | 2024 | |
| Bridgebio Pharma, INC. | $14.84 | 2025 | Attruby |
| Abiomed | $13.19 | 2024 | Impella |
| Itamar Medical INC | $10.38 | 2024 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanna Winter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.